[METRIC]
A-A-53671A
30 August 1993
SUPERSEDING
A-A-0053671
19 October 1988
COMMERCIAL ITEM DESCRIPTION
AURANOFIN CAPSULES
The General Services Administration has authorized the use of this Commercial Item Description.
Salient characteristics:
Shall be Auranofin Capsules.
Shall contain 3 mg Auranofin per capsule, within the applicable assay limits, when assayed by a suitable accurate and reproducible method.
All ingredients shall be of a pharmaceutical grade.
Each capsule shall be marked/embossed with a product identification code to identify the active ingredient(s), strength, and manufacturer. The materials used in the marking/embossing the dosage forms shall be acceptable to the FDA. The actual code used for the product shall be left to the discretion of the supplier.
Workmanship. The capsules shall be free from defects which detract from its appearance or impair its serviceability.
DISTRIBUTION STATEMENT A. Approved for public release; distribution is unlimited.
For Parts Inquires submit RFQ to Parts Hangar, Inc.
© Copyright 2015 Integrated Publishing, Inc.
A Service Disabled Veteran Owned Small Business